The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Communication.

Particular areas of interest include:

• design, results, analysis and interpretation of post-marketing surveillance and other studies looking at specific drugs, populations and outcomes;
• methods for detection and evaluation of drug-associated adverse events;
• assessments of risk and benefit in drug therapy;
• patterns of drug utilization;
• relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
• risk management plans and programmes relating to pharmaceuticals, biologics and medical devices;
• comparative effectiveness research relating to pharmaceuticals, biologics and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as they are truly used in the real world.

2008 Impact Factor: 2.516 (? Thomson Reuters Journal Citation Reports 2009)